相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Elizabeth M. Swisher et al.
GYNECOLOGIC ONCOLOGY (2021)
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
Pierre-Marie Morice et al.
LANCET HAEMATOLOGY (2021)
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Tanya T. Kwan et al.
JAMA ONCOLOGY (2021)
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2
Kim A. Reiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M. Swisher et al.
NATURE COMMUNICATIONS (2021)
Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study
A. Dean et al.
ANNALS OF ONCOLOGY (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Flurina A. M. Saner et al.
NATURE REVIEWS CANCER (2019)
Biomarkers for Homologous Recombination Deficiency in Cancer
Michal M. Hoppe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal
James X. Sun et al.
PLOS COMPUTATIONAL BIOLOGY (2018)
Biomarkers for Homologous Recombination Deficiency in Cancer
Michal M. Hoppe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
Olga Kondrashova et al.
NATURE COMMUNICATIONS (2018)
Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
Graziela Z. Dal Molin et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer
Dale W. Garsed et al.
CLINICAL CANCER RESEARCH (2018)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux et al.
CLINICAL CANCER RESEARCH (2017)
Low-grade serous ovarian cancer: A review
Anis Kaldawy et al.
GYNECOLOGIC ONCOLOGY (2016)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Jianfeng Shen et al.
CANCER DISCOVERY (2015)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ashour Ahmed Ahmed et al.
JOURNAL OF PATHOLOGY (2010)
分享论文
